Conclusions In the STEP-HFpEF program, in patients with obesity-related HFpEF, semaglutide reduced NT-proBNP levels
However, the relationship between the two is even more interesting than a simple "contains" or "doesn't contain" label
In Phase II trials, MariTide demonstrated up to approximately 20% average weight loss at 52 weeks in people living with obesity or overweight, without evidence of a plateau, suggesting even greater results with longer treatment
Furthermore, the neuroprotective effects of green tea on brain cells have been confirmed, indicating its potential for alleviating symptoms of autism when included in the diet at an early stage [120]
If you want this level of customization with active provider support, a platform with more engaged clinical oversight will serve you better than Brello